J Clin Lipidol. 2026 Mar 14:S1933-2874(26)00074-7. doi: 10.1016/j.jacl.2026.03.007. Online ahead of print.
ABSTRACT
BACKGROUND: Despite high cardiovascular risk, many patients with acute coronary syndrome (ACS) do not receive timely intensification of lipid-lowering therapy (LLT).
OBJECTIVE: To predict the impact of LLT intensification on cardiovascular events and attainment of low-density lipoprotein cholesterol (LDL-C) goals in this population.
METHODS: A Monte Carlo simulation was conducted using data from 54,154 patients with ACS to estimate 5-year rates of a composite endpoint of myocardial infarction, ischemic stroke, or cardiovascular death. Three immediate LLT strategies were modeled: (1) high-intensity statin (HIS) + ezetimibe (EZE), (2) HIS + alirocumab (ALI), and (3) HIS + EZE + ALI (triple LLT). Two delayed strategies were also assessed: (1) HIS + EZE at baseline with ALI added at 6 months if LDL-C goals were unmet, and (2) HIS alone at baseline with sequential addition of EZE at 6 months and ALI at 12 months if goals were unmet. LDL-C goals included <55 mg/dL and <40 mg/dL, each with and without ≥50% reduction. Subgroups included patients with prior ischemic stroke or without revascularization during ACS hospitalization.
RESULTS: Triple LLT reduced the predicted 5-year event rate from 22.2% (95% CI: 21.8-22.6) with HIS alone to 14.3% (95% CI: 14.0-14.6), yielding an absolute risk reduction of 8.0% (95% CI: 7.6-8.3) and a relative reduction of 35.8% (95% CI: 34.4-37.2). Predicted benefit was greater in patients with prior ischemic stroke or no revascularization, with LDL-C goals achieved in nearly all patients.
CONCLUSIONS: Triple LLT initiated at ACS hospitalization may markedly reduce cardiovascular events through earlier and more complete achievement of LDL-C targets.
PMID:41935912 | DOI:10.1016/j.jacl.2026.03.007